Dow Jones
35 950,89 +520,47 (+1,47 %) Nasdaq
14 226,22 -32,27 (-0,23 %) Nikkei 225
33 486,59 -0,30 (-0,00 %) EUR/USD
1,0904 +0,0011 (+0,10 %) HANG SENG
16 953,74 -89,14 (-0,52 %) Bitcoin EUR
34 871,68 -13,79 (-0,04 %)
MRK Jun 2024 95.000 call
| Clôture précédente | 11,50 |
| Ouverture | 11,50 |
| Offre | 11,50 |
| Vente | 11,90 |
| Prix d’exercice | 95,00 |
| Date d’expiration | 2024-06-21 |
| Var. jour | 11,50 - 11,50 |
| Gamme de contrats | S.O. |
| Volume | |
| Position de place | 207 |
ACCESSWIREMRNA-4157/V940, an Investigational Personalized MRNA Cancer Vaccine, in Combination With Keytruda(R) (Pembrolizumab), Receives Prime Scheme Designation From the European Medicines Agency for Adjuvant Treatment of Patients With High-Risk Stage III/IV Melanoma Following Complete Resection
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA, Merck's anti-PD-1 therapy, has been granted Priority Medicines (PRIME) scheme designation by the European Medicines Agency (EMA) for the adjuvant
- ACCESSWIRE
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, and Merck (NYSE:MRK), known as MSD outside of the United States and Canada, today announced that the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial of mRNA-4157/V940, an investigational personalized mRNA cancer vaccine, in combination with KEYTRUDA®, Merck's anti-PD-1 therapy, demonstrated a statistically significant and clinically meaningful
